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Resistant Enterococci: Treatment from test 
tubes to animals to humans 
R.C. Moellering, Jr.. Harvard Medical School, Beth Ltrael Deaconecs 
Medical Center, Boston, MA, USA 
The changing patterns of antimicrobial susceptibility of enterococci 
continue to provide challenges for the microbiologist and clinician. 
In vitm testing has provided valuable assistance in the therapy of 
enterococcal mfections and animal models have been used success- 
fuuy to predict c h i d  u a t y  (or lack thereof) of in vim, obser- 
vations. In some cases, animal models have correctly predicted in 
vivo failure of compounds which exhibit in vitm activities (such as 
is true for trimethoprim/sulfamethoxizole) and in other cases they 
have provided explanations for apparent dscrepancies between in 
via0 and dtnical results (as is true for clindamycin/aminoglycoside 
combinations for intrabdominal infections). However, for the most 
part there has been a good correlation among in vitm testing, ani- 
mal model results, and clinical outcome in enterococcal infections. 
The synergistic interaction of combinations of cell-wall active agents 
and aminoglycosides has been confirmed in animal models and in 
clinical Studies as has the likehhood of failure when such combi- 
nations are used against organisms with high-level resistance to the 
aminoglycoside in the combination. Emergence of multiply-resistant 
enterococci (including vancomycin-resistant strains) is now creating 
new challenges. In vim testing and animal models are currently 
being used to discover novel treatment regimens for these multi- 
ply-resistant organisms. 
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EE. Andr6. B 
No abstract available. 
I S1341 The use of interferon and antiviral substances in 
the treatment of chronic hepatitis C 
C. Trautwein, M.P. Manns. Medizinische Hochschule, Hannover, 
-any 
Infection by the hepatitis C virus can lead to chronic hepatitis in 
more than 80% of the patients. Chronic hepatitis C infection is a 
major risk factor for the development of liver cirrhosis or hepatocel- 
lular carcinoma. Therefore therapy of chronic hepatitis C infection 
is a major goal to increase patients survival and to reduce costs which 
are associated with its complications. The only approved therapy to 
treat chronic hepatitis C infection is the admimtration of interferon 
alpha (IFN). At present 3 x 3-5 Mill IU per week are given for 
6 months. The initial response rates are hlgh (40-50%). However 
the long term response is only around 10%. Predictors of response 
for IFN treatment are the genotype of the Virus, the wal load, the 
duration of the infection until the star t  of therapy and the amino- 
mferase  level. Recent studies indicate that longer administration 
(> 18 m) of IFN may have advantages compared to the 6 months 
treatment schedule. In combination with IFN, a new nucleoside 
analogs - ribavirin - has been shown to have benefit for the ehmina- 
tion of the hepatitis C virus in chronic carriers. However only small 
numbers of patients have been treated and the promising first results 
have to be evaluated in larger series of patients. Besides the use of 
interferon and ribavirin, IL12 is now tested in phase I clinical trials. 
First results of its use in pilot studies will soon be available. 
In summary hepatitis C mfection leads to serious complications. 
However the treatment regimes presently available show only little 
benefit on the elinunation of the virus and need further improve- 
ment. 
I S135 I Molecular therapy of chronic viral hepatitis 
H.E. Blum. Department ofMedicine 11, Universiry of Frei6uq, Frei6urg, 
Germany 
The idenhfication of the molecular and genetic basis of many liver 
diseases has lead to a better understanding of their pathogenesis and 
offers new perspectives for their diagnosis, therapy and prevention. 
Genetically, liver diseases can be classified as monogenetic, com- 
plex genetic and acquired genetic diseases. Based on this classlhca- 
tion, hepatitis B virus (HEW) and hepatitis C virus (HCV) infection 
are acquired genetic diseases that can be treated by gene therapy 
aimed at blocking viral gene expression or function at Herent lev- 
els. The best studied genetic antiviral strategies are ribozymes, anti- 
sense oligonucleotides (ON) and dominant negative @N) mutants, 
all of which mhibit viral gene expression in experimental systems. 
Despite exciting recent developments, a number of problems have to 
be solved. Apart h m  their optimal design, some of the major issues 
are the specificity and stability of these therapeutic nucleic acids in 
vivo, their cellular and intracellular targeting as well as the potential 
development of resistance. Even if highly effective and target-spedc 
in vivo, ribozymes, antisense ONs and DN mutants may complement 
rather than replace existing or future therapeutic strategies, e.g., in- 
terferons, nudeoside analogues and peptide or DNA vaccines. Ther- 
apeutic DNA nccination in particular holds great promise as an 
effective molecular therapy of HBV and HCV mfection. 
I S136 ] Laboratory diagnostic parameters in the 
selection for therapy and subsequent follow-up 
of patients sufkring from chronic viral hepatitis 
E Bonino, M.R. Brunetto. Liver Pathology, Dept. of Gastroenterology, 
Molinette Hospital, Torino, Italy 
HEW and HCV are not invariably pathogenic and their genetic het- 
erogeneity could be a major cause of their pathogenetic variability. 
In clinical practice this means that presence and replication of the 
virus do not invariably imply a virus induced liver damage. Igh4 
antibodes appear the best dragnostic tools for etiologic diagnosis, 
however, they are not sensitive and specific enough for hepatitis C. 
The core protein (Sl), the envelope proteins El ,  EZ/NS1 and the 
non structural proteins NS3, NS4 and NS5 of HCV were found to 
induce antibodies against their sequential epitopes. The detection of 
all these antibodies represent and indmct evidence of ongoing HCV 
mfection. Detection of anti-HCV does not help to dlstinguish past 
&om present infections and only anti-HCV seroconversion in previ- 
ously negative patients can indicate a recent infection. In addition, a 
few patients have been shown to carry HCV-RNA in their serum 
or liver being repeatedly antibody negative. In anti-HCV negative 
infections and early acute hepatitis cases HCV-RNA detection d 
represent a valid diagnostic alternative, provided that a correct stan- 
dardization of the techniques and quantitation are performed. In 
patients undergoing antiviral therapy monitoring viremia and anti- 
body levels represent a valid tool to predict response that invariably 
has occurred in patients who had undetectable viremia and/or de- 
creasing antibody titres. 
